Ras Protein Clustering Detection via Nanostructure Arrays
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting protein clustering, particularly for Ras proteins, are inadequate for effective anti-Ras drug screening due to limitations in sensitivity and specificity.
Innovation Solution
A method involving culturing cells on arrays of nanostructures to visualize Ras protein clustering using optical microscopy, where changes in clustering patterns indicate isoform or mutation status, and can predict biological activity and drug efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional enzymatic activity inhibition methods are used, then direct Ras inhibition is attempted, but the high affinity of Ras for GTP and lack of deep pockets prevent effective drug binding
Solution Approach 1:
The patent uses nanobodies as intermediary molecules that bind to Ras proteins. These nanobodies serve as mediators between the drug screening process and the Ras target, enabling detection and inhibition without requiring direct binding to the difficult-to-access enzymatic G-domain. The nanobodies specifically recognize and bind to Ras isoforms and mutants, facilitating drug screening through their clustering behavior.
Solution Approach 2:
The patent replaces traditional biochemical assays with optical microscopy-based detection. Instead of measuring enzymatic activity or binding affinity through complex biochemical mechanisms, the invention uses optical imaging to visualize Ras-nanobody clustering on the cell surface, substituting mechanical/biochemical measurement systems with optical detection systems.
2Reliability
If downsteam signaling protein inhibition is used, then Ras pathway activity is blocked, but compensatory mechanisms and intertwined pathways reduce effectiveness
Solution Approach 1:
The patent performs preliminary detection of Ras clustering status before drug treatment. By using nanobodies to pre-visualize and quantify Ras cluster formation on the cell surface, the system establishes a baseline that predicts downstream signaling activity. This preliminary action allows selection of patients whose tumors are most likely to respond to anti-Ras therapies, preventing waste on patients with compensatory pathway activation.
Solution Approach 2:
The patent implements a feedback mechanism where the degree of Ras clustering detected by nanobodies provides information about downstream signaling status. This feedback is used to predict patient response to therapy, allowing clinicians to adjust treatment strategies based on the actual signaling state of the patient's tumor, thereby overcoming compensatory mechanisms.
3Measurement precision
If conventional drug screening methods are used, then general anti-cancer activity is assessed, but specific anti-Ras clustering inhibition cannot be evaluated
Solution Approach 1:
The patent uses fluorescently labeled nanobodies that emit optical signals when bound to Ras proteins. The fluorescent color changes and clustering patterns provide visual readouts of Ras localization and clustering status. This color-based optical detection method enables precise measurement of Ras clustering that cannot be achieved with conventional biochemical assays.
Solution Approach 2:
The patent transitions from measuring Ras activity in a single-dimensional biochemical assay to visualizing Ras clustering in spatial dimensions using optical microscopy. By detecting the spatial distribution and clustering patterns of Ras-nanobody complexes on the cell surface, the invention adds spatial dimensionality to the measurement, enabling detection of clustering phenomena that conventional methods cannot capture.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables precise detection of Ras protein clustering, facilitating the identification of specific isoforms or mutations, and predicting the efficacy of anti-Ras drugs, thereby aiding in drug screening and cancer diagnosis.
Implementation Method 1
visualizing the Ras protein using optical microscopy to detect clustering of the Ras protein around the plurality of nanostructures
Data Source
AI summary
The present invention relates to a method of detecting clustering of Rat Sarcoma Vims (Ras) protein in a cell comprising culturing the cells on an array of nanostructures and detecting the clustering of Ras protein around the nanostructures by using optical microscopy. In one embodiment, the nanostructures are nanobars. The invention further relates to the use of the method in identifying the isoform or mutation status of Ras protein, and anti-Ras drug screening.